BC Extra | Mar 13, 2019
Preclinical News

Langer study describes once-monthly dosing system for tuberculosis

The scientific team behind drug delivery company Lyndra Therapeutics described a delivery device capable of releasing large payloads into the stomach over several weeks in a paper published in Science Translational Medicine on Wednesday. While...
BC Week In Review | Jul 13, 2017
Company News

Almirall lowers guidance

Almirall S.A. (Madrid:ALM) lowered its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared to 2016, and it guided to EBITDA of...
BC Extra | Jul 10, 2017
Financial News

Almirall sags after lowering guidance

Almirall S.A. (Madrid:ALM) fell €3.21 (25%) to €9.80 on Monday after lowering its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared...
BC Week In Review | Aug 11, 2014
Clinical News

Acticlate doxycycline hyclate regulatory update

Almirall’s Aqua Pharmaceuticals LLC unit said FDA approved an NDA for Acticlate doxycycline hyclate to treat several infections, including adjunctive treatment of severe acne. The company plans to begin marketing the oral tetracycline antibiotic “in...
BC Week In Review | Apr 22, 2013
Clinical News

Doryx doxycycline hyclate delayed-release tablet regulatory update

FDA approved a 200 mg dose of tetracycline oral antibiotic Doryx doxycycline hyclate delayed-release tablet from Mayne's U.S. marketing partner Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland). Warner Chilcott plans to launch the dose in July....
BC Week In Review | May 7, 2012
Company News

Warner Chilcott, Impax, Mylan infectious news

Warner Chilcott said the U.S. District Court for the District of New Jersey ruled in favor of Mylan and Impax in a patent infringement suit brought by Warner Chilcott related to a generic version of...
BC Week In Review | Oct 24, 2011
Clinical News

Doryx doxycycline hyclate delayed-release tablet regulatory update

FDA accepted for filing a Citizen's Petition from Mayne's marketing partner Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) asking the agency not to grant final approval of ANDAs for generic versions of 150 mg Doryx doxycycline...
BC Extra | Feb 17, 2004
Clinical News

CGPI rosacea Phase III data

CollaGenex (CGPI) said preliminary data from a Phase III trial in 134 patients with rosacea showed that Periostat doxycycline hyclate tablets significantly reduced the number of inflammatory lesions compared to placebo (p=0.009). Clinical disease severity...
BC Week In Review | Aug 19, 2002
Clinical News

Periostat doxycycline: Phase III; marketed to treat periodontal disease

CGPI started a double-blind U.S. Phase III trial of its Periostat in up to 210 patients with rosacea, a chronic inflammatory disease characterized by redness of skin and lesions. CollaGenex Pharmaceuticals Inc. (CGPI), Newtown, Penn....
BioCentury | Feb 22, 1999
Tools & Techniques

Inflection points

As news watchers come to realize, seemingly independent events have a way of piling up on themselves and pushing other topics into the background. With the stars thus aligned, it becomes impossible to ignore the...
Items per page:
1 - 10 of 11